Peer Review History
| Original SubmissionSeptember 9, 2019 |
|---|
|
PONE-D-19-25095 Discontinuous transcription of ribosomal DNA in human cells PLOS ONE Dear Dr. Smirnov, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses all the points raised during the review process. In particular: 1. your data would benefit of better presentation including laid out rationales for the experiments/choice of experimental approaches (see Rev 1), presentation of individual data points (as suggested by Rev 2), extended discussion (including clarifying the issue of novelty as identified by Rev 3 as well as stress recovery effects- Rev 2), fixed issues with figure numberings, abbreviations, full descriptions of statistics. 2. Confirming findings with 5FU using another approach is critical for interpretation of your current data (see comments by Rev 2 and Rev 3) We would appreciate receiving your revised manuscript by 60 days from the date of this decision letter. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Michal Hetman Academic Editor PLOS ONE Journal Requirements: 1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for including your ethics statement "The study followed the standards of the Ethics Committees of the General Teaching Hospital and the First Faculty of Medicine of Charles University, Prague, Czech Republic (Ethics Committee of General Univeristy Hospital, Prague approval no. 8/14 held on January 23, 2014), and adhered to the tenets set out in the Declaration of Helsinki. We obtained human cadaver corneoscleral rims from 10 donors, which were surplus from surgery and stored in Eusol-C (Alchimia, Padova, Italy), from the Department of Ophthalmology, General University Hospital in Prague, Czech Republic, for the study. On the use of the corneoscleral rims, based on Czech legislation on specific health services (Law Act No. 372/2011 Coll.), informed consent is not required if the presented data are anonymized in the form." a) Please amend your current ethics statement to confirm that your named institutional review board or ethics committee specifically approved this study. b) Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”). For additional information about PLOS ONE ethical requirements for human subjects research, please refer to " ext-link-type="uri" xlink:type="simple">http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research." 3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide. 4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data. Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No Reviewer #3: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No Reviewer #3: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The paper by Eugene Smirnov et al. describes the analysis of rDNA expression during about 2 h after release of human cells from cold treatment. FU incorporation was reduced by the cold treatment and the signal reached the normal level after 30 min of incubation at 37°C. Using transfected plasmid carrying Pol I gene fused with GFP or GFP-Fibrillarin construct they observed that cold treatment reduced the levels of Pol I in the FC/DFC units. In subsequent experiments they demonstrated that there are fluctuations of incorporated FU in the whole nucleoli during 120-150 min. The experimental data confirm the conclusion that rDNA genes are transcribed discontinuously during short period after incubation at 37°C. The paper should be re-written. Authors should first describe all experiments in the text in more detail. E.g., why they use this particular experiment in the text. why they use the transfections with Pol I gene and Fibrillarin gene. How they measure the intensity and amplitude. What are a.u. and a.e. units? What secondary Ab were used in FU detection? Each panel in the Figure should be described. Reviewer #2: The work describes the study of discontinuous expression of rRNA genes. This manuscript builds on their previous work published in the Nucleus journal. In a new work, the authors investigated discontinuous expression of ribosomal genes after inhibition of transcription using cold stress. It seems that the data presented are not enough to convincingly illustrate the assumptions made. 1. The main emphasis in the work is made on the analysis of the intensity of label (FU) incorporation into the nucleoli of cultured cells. However, the inclusion of FU depends not only on the intensity of expression, but also on the rate of its cellular uptake and phosphorylation in the cell. Therefore, confirmation of this key result by an independent method is necessary. The authors show in Fig. 2 and 3A (and in their previous work, this was also demonstrated) that the nucleolur accumulation of RPA 43 also changes with time. It is possible to confirm the presence of waves of intensity of ribosomal RNA expression using this method. The live cell imaging of RPA 43 during during the recovery of cells after cold stress (with estimations and statistical analysis) can illustrate described waves more accurately than the estimation of FU incorporation for overall cell population. 2. The authors indicate that the data on fluctuations and transcription cycles were obtained by averaging over several experiments (8 repetitions). It seems that it is necessary to present not only the result of averaging over 8 experiments, but also the curves for all individual experiments (plus, the result of averaging). To appreciate how is the distribution of averaged values among the time points, instead of using bar graphs the data should be represented using box-plots with the individual values as dots. Also, the statistical analysis of detected fluorescence intensity fluctuations should be presented. These changes were statistically significant or not? 3. I think that the experimental model used (restoration of transcription after cold stress) cannot be interpreted as synchronization. For human cells, this is very severe stress. And it seems that the subsequent processes should be interpreted as a process of recovery from stress. In this case, the transcription fluctuations can be connected with the process of cell restoration, which may differ from fluctuations in the control culture (which was described in the article in the Nucleus journal). Authors should at least briefly discuss such an interpretation of their data. Reviewer #3: The main goal of the study by Smirnov et al. “Discontinuous transcription of ribosomal DNA in human cells” was to evaluate nucleolar and nucleoplasmic transcription in two types of human cells (HeLa and epithelial limbal cells) after their synchronization with a low (4o C) temperature followed be the release from the cold shock as compared with untreated controls. Aims were reached by incubation of cells with 5-fluorouridine as precursor of RNA synthesis, expression of plasmids encoding RNA pol I subunit (RPA43) and fibrillarin fused with GFP. The intensity and number of signals were examined using a MatLab based software [ref 51] and Image J facilities. The authors concluded that: (1) chilling of cells results in arrest of pol I (nucleolar) and pol II (nucleoplasmic) transcription but does not displace all pol I complexes from their intrinsic locations; (2) cell release from the chilling conditions restores rDNA transcription to control values; (3) the restoration of rDNA transcription follows a wave-like manner (within 15-210 min of observation) and is discontinuous process. Comments: The major question concerns the principal novelty of the reviewed paper as compared with the papers recently published by the same authors in “Nucleus” (M. Hornáček et al., Fluctuations of pol I and fibrillarin contents of the nucleoli. Nucleus, 2017, 8: 421-432; Smirnov et al., Discontinuous transcription Nucleus, 2018, 9: 149-160). In both publications, it is stated that ribosomal genes, like other genes, are transcribed in pulse-like manner (e.g., Hornáček et al., 2018, page 150), while it is well known that rRNA genes are transcribed during the entire cell cycle [ref. 49], which duration is much longer (roughly 24 hours) than the duration of observations in the current study (150-210 min). Minor questions: Lines 25, 89 “in the populations of tumour derived” – Unclear meaning Line 92: Methods Conditions for cell chilling should be described in this section instead of Results. Lines 159, 160 (Fig 1) – It is unclear, where are the nuclear boundaries, and how the authors determined that “… FU is accumulated predominantly in the FC/DFC units of the nucleoli” without using any markers for FC/DFC? Lines 187, 190 (legend for Figure 3): “bars” should apparently be replaced by “columns”. Fig.3A: What are the vertical bars: SEM or standard deviation (Ϭ). Fig. 3B: SEMs (or Ϭ) are not indicated. Lines 193, 194: It is remained unspecified how the authors distinguish between negative labeling of cells with 5-FU (5-fluorouridine) caused by inhibition of rDNA transcription from non-penetration of the precursor in cells in cold conditions. In addition, before incorporation in nascent pre-rRNA FU must be bound to ATP and this process most likely is suppressed by a low temperature. By other words, 5-FU was unincorporated not because genes were not transcribed, but because the precursor was inaccessible to nascent RNAs upon cold conditions. Fig. 4 (Lines 207-213). A – there are no SEM (or Ϭ) on the columns and therefore it is impossible to compare differences between various time-points statistically. The latter makes the authors statement about a fluctuating manner of rDNA transcription uncertain. B – on the periodograms, the horizontal axis scale does not correspond to the relative graphs in Fig. 4A. Fig. 5 (Lines 241-246): See comments to Fig. 4. Fig. 6 (Lines 264-267): See comments to Fig. 4. The images below Fig. 7 are not described (are they copies?). Unfortunately, figures are not numbered that makes their identification complicated. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-19-25095R1 Discontinuous transcription of ribosomal DNA in human cells PLOS ONE Dear Dr. Smirnov, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Those include: -clarifying statistical analysis results as pointed by Rev#2 -reorganizing the abstract to reflect the revised content accurately (as pointed by Rev#3) -clarifying the methods section as suggested by Rev#3 We would appreciate receiving your revised manuscript in 30 days from the date of this decision letter. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Michal Hetman Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: No Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Synchronized HeLa and LEC cells demonstrated two successive peaks of rDNA transcription. These picks are now presented for individual cells and for averaging. The text and Legends to Figures in the revised paper include the details that help a reader to understand the paper. All my concerns were addressed. Reviewer #2: Minor questions 1. Line 336. The usual p-value in t-test is 0.05. 2. The data in Fig. 4A and 5A. Is each curve based on a measurement of 50 cells? Maybe then it is worth presenting for each point the data not only on the mean, but also the standard deviation? 3. The new figures are not embedded in the logic of the article. In the current version, the last panel with box-plot in fig. 4a and fig. 4b (+ last panel with box-plot in 5a and fig. 5b) duplicate each other. 4. It is not clear why the error bars for the control cells are not provided (Fig. 4B and Fig. 5B, right panels)? Reviewer #3: Comments to the revised version of the paper by Smirnov et al. “Discontinuous transcription of ribosomal DNA in human cells” In general, the authors took into account my comments and adequately answered the questions. However: (1) The Abstract remains almost unchanged. For example, it does not include mentioning the results of BrUTP experiments, which were included to the revised paper (lines 176-183). According to my opinion, these experiments are crucially important for interpretation of the FU-labeling data. The same is also true for the last paragraph of Introduction, where the authors summarize the main paper results. (2) Methods It remains unclear, why the BrUTP labeling protocol is described only “briefly” (line 135). The publications cited by the authors for the scratch procedure used in the current study [55, 56] apply cell labeling with DNA replication but not with any transcription precursors. What was the duration of cell fixation with methanol (line 133)? What was the working concentration of BrUTP? Line 140: “cy3-conjugated” should be replaced by “Cy3-conjugated”. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Discontinuous transcription of ribosomal DNA in human cells PONE-D-19-25095R2 Dear Dr. Smirnov, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Michal Hetman Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-19-25095R2 Discontinuous transcription of ribosomal DNA in human cells Dear Dr. Smirnov: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Michal Hetman Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .